$RIGL appears Grifols has many different entry points it's testing. Latest: NAID Phase 3 did not meet primary endpoint. "Co announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial, also known as INSIGHT-013, sponsored and supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its primary endpoints with statistically significant results. The company will continue to move forward with its work on more than 20 research initiatives to find potential treatment options for different stages of COVID-19." More at the link... briefing.com/in-depth-analy...